PBT-1 Prana Biotechnology.
PBT-1 (clioquinol), is undergoing phase II clinical trials by Prana Biotechnology Ltd for the potential treatment of Alzheimer's disease. By October 2004, the company had planned phase III trials for the first half of 2005.
Huckle
Richard
R
Axovan Ltd, Innovation Center, Allschwil, Switzerland. richard@huckle2.fsbusiness.co.uk
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D002986:Clinical Trials as Topic; D007464:Clioquinol / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans
D016229:Amyloid beta-Peptides; D007464:Clioquinol